Peptides News and Research

RSS

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

Study of twins reveals differences in adaptive immunity towards SARS-CoV-2

Twins may look alike on the outside, but not so much on the inside. That's one takeaway from a new preprint study posted to the medRxiv server where Brazilian researchers observed different T-cell responses in two pairs of identical twins exposed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One twin who was reinfected with SARS-CoV-2 four months after had low recognition of CD4+ and CD8+ T-cell epitopes.

31 Mar 2021

Imported COVID-19 cases responsible for spread of the UK and Brazil SARS-CoV-2 variants in Italy

A new study examines a major consequence of the second wave of COVID-19 infection—namely, the rapid emergence of new viral lineages and variants.

30 Mar 2021

Linear epitope mapping of the SARS-CoV-2 spike protein

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the primary target of many drug discovery efforts and is similarly utilized in each of the approved COVID-19 vaccines to elicit the generation of anti-spike protein antibodies, thereby granting immunity.

28 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Dr. Hans Maric has received one of the German Research Foundation's highly prestigious Emmy Noether awards, worth around 1.7 million euros.

25 Mar 2021

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

Despite continued improvements in antibiotics and hospital intensive care, staph sepsis - a bloodstream infection caused by Staphylococcus aureus bacteria - still causes severe illness or death in 20 to 30 percent of patients who contract it.

24 Mar 2021

New compound may provide a basis for drug development against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Review: Using biomaterials in dental implants

Announcing a new article publication for BIO Integration journal. In this review article the authors Oliver K. Semisch-Dieter, Andy H. Choi and Martin P. Stewart from the University of Technology Sydney, Ultimo, NSW, Australia discuss the use of biomaterials in dental implants.

22 Mar 2021

Bacteria residing within tumor cells can boost cancer immunotherapy

Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells.

22 Mar 2021

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Co-founded back in 2014 by VHIO's Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).

19 Mar 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

Using nanoparticles for efficient delivery of antimicrobial peptides to treat deep infections

Announcing a new article publication for BIO Integration journal. In this review article the authors Yingxue Deng, Rui Huang, Songyin Huang and Menghua Xiong from South China University of Technology, Guangzhou, Guangdong, P. R. China and Sun Yat-sen University, Guangzhou, Guangdong, P. R. China discuss how nanoparticles enable efficient delivery of antimicrobial peptides for the treatment of deep infections.

18 Mar 2021

SARS-CoV-2 Brazilian variant may potentially escape T cell-mediated host immune responses

A team of scientists from Brazil recently explored the abilities of the UK, South African, and Brazilian variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evade host CD8+ T cell responses induced by natural infection or vaccination. The findings reveal reduced antigenic coverage for the P.2 Brazilian lineage, indicating its ability to evade SARS-CoV-2-induced T cell responses.

16 Mar 2021

48Hour Discovery and Merck join hands to accelerate drug development

48Hour Discovery and CQDM are proud to announced that the company has been awarded $800,000 for peptide drug discovery using its patented drug discovery platform.

15 Mar 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.

12 Mar 2021

New approach could treat infertility caused by abnormal GnRH secretion

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule that governs the reproductive function in men and women by regulating the release of a range of reproductive hormones into the body, particularly gonadotropins, from the pituitary gland, which is located underneath the brain.

12 Mar 2021

Peptides News and Research

Development of a model of substrate coordination to Zn-bound ACE2

Study of twins reveals differences in adaptive immunity towards SARS-CoV-2

Imported COVID-19 cases responsible for spread of the UK and Brazil SARS-CoV-2 variants in Italy

Linear epitope mapping of the SARS-CoV-2 spike protein

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

New compound may provide a basis for drug development against COVID-19

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Review: Using biomaterials in dental implants

Bacteria residing within tumor cells can boost cancer immunotherapy

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Developing a COVID-19 vaccine using inactivated E. coli

Using nanoparticles for efficient delivery of antimicrobial peptides to treat deep infections

SARS-CoV-2 Brazilian variant may potentially escape T cell-mediated host immune responses

48Hour Discovery and Merck join hands to accelerate drug development

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

New approach could treat infertility caused by abnormal GnRH secretion

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News